178 related articles for article (PubMed ID: 24111178)
61. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
62. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
Qin H; Jiang Y; Zhang J; Deng C; Zhong Z
Mol Pharm; 2019 Aug; 16(8):3711-3719. PubMed ID: 31299161
[TBL] [Abstract][Full Text] [Related]
63. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.
Boulikas T
Expert Opin Investig Drugs; 2009 Aug; 18(8):1197-218. PubMed ID: 19604121
[TBL] [Abstract][Full Text] [Related]
64. Preliminary data by cis-platin and etoposide using in primary glioblastoma.
Milanesi I; Silvani A; Munari L; Solero CL; Botturi M; Boiardi A
J Neurosurg Sci; 1990; 34(3-4):279-82. PubMed ID: 1965906
[TBL] [Abstract][Full Text] [Related]
65. 3D optical/CT as a preclinical companion imaging platform for glioblastoma drug development.
Molotkov A; Doubrovin M; Bhatt N; Hsu FC; Beserra A; Chopra R; Mintz A
Drug Deliv; 2020 Dec; 27(1):1686-1694. PubMed ID: 33263448
[TBL] [Abstract][Full Text] [Related]
66. Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma.
Zhang Y; Zhang L; Hu Y; Jiang K; Li Z; Lin YZ; Wei G; Lu W
J Control Release; 2018 Nov; 289():102-113. PubMed ID: 30243823
[TBL] [Abstract][Full Text] [Related]
67. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
68. New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it.
Peschillo S; Caporlingua A; Diana F; Caporlingua F; Delfini R
J Neurointerv Surg; 2016 Oct; 8(10):1078-82. PubMed ID: 26541791
[TBL] [Abstract][Full Text] [Related]
69.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
70. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
[TBL] [Abstract][Full Text] [Related]
71. Focused Ultrasonography-Mediated Blood-Brain Barrier Disruption in the Enhancement of Delivery of Brain Tumor Therapies.
Zaki Ghali MG; Srinivasan VM; Kan P
World Neurosurg; 2019 Nov; 131():65-75. PubMed ID: 31323404
[TBL] [Abstract][Full Text] [Related]
72. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Wang L; Liu Q; Zhao H; Cui K; Yao L; Nie F; Jin G; Hao A; Wong ST
J Neurosci Res; 2013 Jan; 91(1):128-37. PubMed ID: 23115024
[TBL] [Abstract][Full Text] [Related]
73. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy.
Madajewicz S; Chowhan N; Tfayli A; Roque C; Meek A; Davis R; Wolf W; Cabahug C; Roche P; Manzione J; Iliya A; Shady M; Hentschel P; Atkins H; Braun A
Cancer; 2000 May; 88(10):2350-6. PubMed ID: 10820358
[TBL] [Abstract][Full Text] [Related]
74. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
75. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment.
Zhang CX; Zhao WY; Liu L; Ju RJ; Mu LM; Zhao Y; Zeng F; Xie HJ; Yan Y; Lu WL
Oncotarget; 2015 Oct; 6(32):32681-700. PubMed ID: 26418720
[TBL] [Abstract][Full Text] [Related]
76. Neutrophil Delivered Hollow Titania Covered Persistent Luminescent Nanosensitizer for Ultrosound Augmented Chemo/Immuno Glioblastoma Therapy.
Li Y; Teng X; Wang Y; Yang C; Yan X; Li J
Adv Sci (Weinh); 2021 Sep; 8(17):e2004381. PubMed ID: 34196474
[TBL] [Abstract][Full Text] [Related]
77. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
78. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Buccarelli M; Marconi M; Pacioni S; De Pascalis I; D'Alessandris QG; Martini M; Ascione B; Malorni W; Larocca LM; Pallini R; Ricci-Vitiani L; Matarrese P
Cell Death Dis; 2018 Aug; 9(8):841. PubMed ID: 30082680
[TBL] [Abstract][Full Text] [Related]
79. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
[TBL] [Abstract][Full Text] [Related]
80. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
Hendricks BK; Cohen-Gadol AA; Miller JC
Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
